Literature DB >> 28983935

Semiparametric accelerated failure time cure rate mixture models with competing risks.

Sangbum Choi1, Liang Zhu2, Xuelin Huang3.   

Abstract

Modern medical treatments have substantially improved survival rates for many chronic diseases and have generated considerable interest in developing cure fraction models for survival data with a non-ignorable cured proportion. Statistical analysis of such data may be further complicated by competing risks that involve multiple types of endpoints. Regression analysis of competing risks is typically undertaken via a proportional hazards model adapted on cause-specific hazard or subdistribution hazard. In this article, we propose an alternative approach that treats competing events as distinct outcomes in a mixture. We consider semiparametric accelerated failure time models for the cause-conditional survival function that are combined through a multinomial logistic model within the cure-mixture modeling framework. The cure-mixture approach to competing risks provides a means to determine the overall effect of a treatment and insights into how this treatment modifies the components of the mixture in the presence of a cure fraction. The regression and nonparametric parameters are estimated by a nonparametric kernel-based maximum likelihood estimation method. Variance estimation is achieved through resampling methods for the kernel-smoothed likelihood function. Simulation studies show that the procedures work well in practical settings. Application to a sarcoma study demonstrates the use of the proposed method for competing risk data with a cure fraction.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  competing risks; cure fraction; kernel smoothing; mixture model; nonparametric likelihood; subdistribution

Mesh:

Year:  2017        PMID: 28983935     DOI: 10.1002/sim.7508

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  1 in total

1.  Linking Tumor Growth Dynamics to Survival in Ipilimumab-Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling.

Authors:  Yan Feng; Xiaoning Wang; Satyendra Suryawanshi; Akintunde Bello; Amit Roy
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-08-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.